```html

Quinone‑Deficiency Hemolytic Anemia

Overview

Quinone‑deficiency hemolytic anemia (QDHA) is a rare, inherited disorder in which red blood cells (RBCs) are unable to maintain normal levels of reduced nicotinamide adenine dinucleotide phosphate (NADPH) because of a deficiency in the enzyme glucose‑6‑phosphate dehydrogenase (G6PD)** or, less commonly, other enzymes of the pentose‑phosphate pathway that generate quinones such as riboflavin (vitamin B2). The lack of quinone cofactors makes RBC membranes susceptible to oxidative damage, leading to premature destruction (hemolysis).

While the term “quinone‑deficiency” is not widely used in clinical practice, it captures the biochemical basis of a subset of hemolytic anemias that result from impaired quinone (or NADPH) generation. The condition is most commonly seen in males of African, Mediterranean, or Asian descent because the G6PD gene is located on the X chromosome.

Prevalence: Over 400 million people worldwide have G6PD deficiency—the most common enzymatic cause of quinone‑deficiency hemolysis—making it the most prevalent human enzyme defect. The overall prevalence of clinical QDHA (i.e., symptomatic hemolysis) is lower, estimated at 1–5% of individuals with G6PD deficiency depending on trigger exposure and genetic variant<sup>1</sup>.

Symptoms

Symptoms may appear rapidly (within hours) after exposure to an oxidative trigger, or develop gradually in chronic‑low‑level hemolysis. The severity ranges from mild fatigue to life‑threatening anemia.

• Fatigue / Weakness – Result of reduced oxygen‑carrying capacity.
• Pallor – Noticeable especially on the face, conjunctivae, and nail beds.
• Jaundice – Yellowing of skin and sclera due to elevated bilirubin from RBC breakdown.
• Dark urine (hemoglobinuria) – Red‑brown urine when large amounts of free hemoglobin are filtered.
• Back or abdominal pain – Often due to splenic enlargement (splenomegaly) or gallbladder sludge from bilirubin.
• Rapid heart rate (tachycardia) – Compensatory response to anemia.
• Shortness of breath – Especially on exertion.
• Headache / Dizziness – From reduced cerebral oxygenation.
• Fever – May accompany an associated infection or severe hemolysis.
• Splenomegaly – Chronic hemolysis can cause the spleen to enlarge.
• Gallstones (pigment stones) – Long‑term bilirubin excess can precipitate stones.

Causes and Risk Factors

Primary cause – Enzyme deficiency

Most cases stem from a genetic deficiency of G6PD, an X‑linked enzyme that generates NADPH, the reducing power needed to keep glutathione in its active form. Other rare enzyme defects (e.g., phosphoglucomutase‑1 or riboflavin kinase) can also impair quinone production and produce a similar clinical picture.

Triggers that precipitate hemolysis

• Medications – Sulfa drugs (e.g., sulfamethoxazole/trimethoprim), quinine, dapsone, nitrofurantoin, certain antimalarials (primaquine, chloroquine), and some NSAIDs.
• Infections – Viral (e.g., hepatitis, influenza) or bacterial infections raise oxidative stress.
• Foods – Fava beans (favism) are a classic trigger; also certain legumes and menthol‑containing products.
• Chemicals – Exposure to naphthalene (mothballs) or industrial oxidants.

Risk factors

• Male sex (X‑linked inheritance)
• Ethnicity: African, Mediterranean (e.g., Greek, Italian), Middle Eastern, Southeast Asian, and certain Indian populations.
• Family history of G6PD deficiency or hemolytic anemia.
• Living in malaria‑endemic regions (historically the mutation confers protection).

Diagnosis

Clinical evaluation

Physicians start with a detailed history (family, ethnicity, recent drug/food exposures) and a physical exam looking for pallor, jaundice, splenomegaly, and signs of dehydration.

Laboratory tests

• Complete blood count (CBC) – Typically shows normocytic anemia with reticulocytosis (↑ reticulocyte count) indicating bone‑marrow response.
• Peripheral smear – May reveal bite cells, Heinz bodies (visible with special stain), and spherocytes.
• Lactate dehydrogenase (LDH) – Elevated due to RBC destruction.
• Haptoglobin – Decreased because it binds free hemoglobin.
• Total & direct bilirubin – Indirect bilirubin rises markedly.
• Urinalysis – Positive for hemoglobin without red cells (hemoglobinuria).
• G6PD enzyme assay – Quantitative measurement of G6PD activity in RBCs. Must be performed when the patient is not in an acute hemolytic episode, as reticulocytes have higher G6PD levels.
• Genetic testing – DNA sequencing can identify specific G6PD variants (e.g., Mediterranean, Mahidol, A‑, or African A‑). Helpful for counseling and prenatal testing.

Additional investigations (if needed)

• Abdominal ultrasound – evaluates splenomegaly or gallstones.
• Coombs test – negative in QDHA, helping to rule out autoimmune hemolytic anemia.

Treatment Options

Acute management

• Remove the trigger – Discontinue offending drug, avoid fava beans, and treat underlying infection.
• Hydration – Intravenous fluids to maintain renal perfusion and help clear hemoglobin.
• Transfusion – Packed RBCs for severe anemia (hemoglobin < 7 g/dL) or symptomatic patients.
• Folate supplementation – 1 mg oral folic acid daily accelerates RBC production.

Preventive/ chronic care

• Medications to avoid – Maintain a personal “drug‑alert” card listing contraindicated drugs.
• Antioxidant support – While routine high‑dose vitamin C or E has not shown clear benefit, a balanced diet rich in antioxidants (fruits, vegetables) is recommended.
• Vaccinations – Influenza and pneumococcal vaccines reduce infection‑related oxidative stress.
• Folic acid – Continue 1 mg daily lifelong to support erythropoiesis.

Experimental/adjunctive therapies

Research is examining N‑acetylcysteine and other glutathione‑replenishing agents, but they remain investational and are not standard of care<sup>2</sup>.

Living with Quinone‑Deficiency Hemolytic Anemia

Daily management tips

• Carry an emergency card listing the condition, known triggers, and emergency contacts.
• Read medication labels – Use apps or pharmacy alerts to flag sulfa drugs, quinine, and antimalarials.
• Dietary vigilance – Avoid fava beans, broad beans, and products that may contain them; ask about hidden sources in herbal supplements.
• Stay hydrated – Aim for at least 2 L of water daily unless fluid‑restricted for another condition.
• Regular follow‑up – Check CBC and reticulocyte count every 6–12 months, or sooner after any hemolytic episode.
• Pregnancy considerations – G6PD deficiency can affect fetal RBCs; prenatal counseling and avoidance of triggers are essential.
• Travel planning – Obtain a list of safe antimalarial prophylaxis (e.g., atovaquone‑proguanil) and keep it with you.

Psychosocial aspects

Because the disorder is lifelong, patients may feel anxious about accidental exposures. Support groups (e.g., G6PD Deficiency Foundation) and counseling can improve coping and adherence.

Prevention

• Newborn screening – Many countries include G6PD testing in routine neonatal panels; early identification allows education before first exposure.
• Family screening – Offer testing to siblings, especially males, and to female carriers (who may have milder symptoms).
• Education of healthcare providers – Ensure prescribers are aware of the condition to avoid contraindicated drugs.
• Genetic counseling – For couples with a known deficiency, discuss risks for offspring.

Complications

If hemolysis is recurrent or severe, several complications may arise:

• Acute kidney injury – Hemoglobin casts can obstruct renal tubules.
• Chronic anemia – May lead to fatigue, reduced exercise tolerance, and cardiac strain.
• Splenomegaly & hypersplenism – Can exacerbate anemia and cause thrombocytopenia.
• Pigment gallstones – From chronic bilirubin overload; may require cholecystectomy.
• Intra‑uterine or neonatal jaundice – High bilirubin levels can cause kernicterus if untreated.
• Increased infection risk – Anemia and splenomegaly can impair immune response.

When to Seek Emergency Care

References

1. World Health Organization. WHO Technical Report Series, No. 1012. Global Prevalence of G6PD Deficiency. 2021.
2. Kaplan, M., & Hsia, H. (2022). Antioxidant therapies for G6PD deficiency: A systematic review. Blood Reviews, 46, 100837.
3. Mayo Clinic. “G6PD deficiency.” Accessed June 2026. https://www.mayoclinic.org
4. Cleveland Clinic. “Hemolytic anemia.” Accessed June 2026. https://my.clevelandclinic.org
5. National Institutes of Health. “Genetics Home Reference: G6PD gene.” Updated 2024. https://ghr.nlm.nih.gov

```